02962nas a2200349 4500008004100000245014800041210006900189260001400258300001200272490000600284520190300290653001702193653004702210653001502257653001902272653001902291100001802310700002002328700001702348700001902365700001502384700001402399700001802413700001902431700001602450700001602466700002302482700001702505700001302522700001202535856006502547 2015 eng d00aAnalgesic and Anti-Inflammatory Effect of UP3005, A Botanical Composition Containing Two Standardized Extracts of Uncaria gambir and Morus alba0 aAnalgesic and AntiInflammatory Effect of UP3005 A Botanical Comp cJune 2015 as39-s460 v73 a

Background: Osteoarthritis (OA) is a chronic debilitating degenerative joint disease characterized by cartilage degradation and synovial inflammation exhibited by clinical symptoms such as joint swelling, synovitis, and inflammatory pain. Present day pain relief therapeutics heavily relies on the use of prescription and over the counter nonsteroidal anti-inflammatory drugs as the first line of defense where their long-term usage causes detrimental gastrointestinal and cardiovascular-related side-effects. As a result, the need for evidence based safer and efficacious alternatives from natural sources to overcome the most prominent and disabling symptoms of arthritis is a necessity. Materials and Methods: Describe the anti-inflammatory and analgesic effect of UP3005, a composition that contains a standardized blend of two extracts from the leaf of Uncaria gambir and the root bark of Morus alba in carrageenan-induced rat paw edema, abdominal constriction (writhing's) and ear swelling assays in mouse with oral dose ranges of 100-400 mg/kg. Results: In vivo, statistically significant improvement in pain resistance, and suppression of paw edema and ear thickness in animals treated with UP3005 were observed compared with vehicle-treated diseased rats and mice. Ibuprofen was used a reference compound in all the studies. In vitro, enzymatic inhibition activities of UP3005 were determined with IC50 values of 12.4 μg/ml, 39.8 μg/ml and 13.6 μg/ml in cyclooxygenase-2 (COX-1), COX-2 and lipoxygenase (5-LOX) enzyme activity assay, respectively. Conclusions: These data suggest that UP3005, analgesic and anti-inflammatory agent of botanical origin with balanced dual COX-LOX inhibition activity, could potentially be used for symptom management of OA.

10aChronic pain10aCyclooxygenase-lipoxygenase dual inhibitor10aMorus alba10aosteoarthritis10aUncaria gambir1 aYimam, Mesfin1 aLee, Young-Chul1 aKim, Tae-Woo1 aMoore, Breanna1 aJiao, Ping1 aHong, Mei1 aKim, Hyun-Jin1 aNam, Jeong-Bum1 aKim, Mi-Ran1 aOh, Jin-Sun1 aCleveland, Sabrina1 aHyun, Eu-Jin1 aChu, Min1 aJia, Qi uhttps://phcogres.com/article/2015/7/5s/1041030974-8490157995